Metin HALAÇ, Meftune ÖZHAN, Sabire Yilmaz AKSOY, Betül VATANKULU, Anar ALIYEV, Sertaç ASA, Ersan ATAHAN, Muhammet Sait SAĞER, Kerim SÖNMEZOĞLU

The role of FDG-PET/CT in detecting unsuspected and unknown distant metastasis in the initial staging of NSCLC

Our purpose in this retrospective study was to determine the ratio of unexpected [metastases within the coverage area of thorax computed tomography (CT)] and unknown (metastases out of the coverage area of thorax CT) metastases by positron emission tomography/CT (PET/CT) in patients with newly diagnosed non-small cell lung cancer (NSCLC) who had no defined metastatic lesion, and to investigate the contribution of fludeoxyglucose (FDG)-PET/CT in metastasis staging. Materials and methods: A total of 567 patients (489 males and 78 females, mean age 60.9 ± 10.7 years) were enrolled in this study. Among the 567 patients, a total of 156 patients who underwent PET/CT for metabolic characterization (group 1) and had solitary pulmonary nodules (group 1a, n = 39) or solitary pulmonary masses (group 1b, n = 117) and the remaining 411 patients (group 2) with NSCLC who had PET/CT performed for staging formed the basis of this study. Results: In group 1, 5/39 (12.8%) patients with a solitary pulmonary nodule and 29/117 (24.8%) patients with a solitary pulmonary mass had distant metastases. In group 2, 129 patients of 411 (31.4%) had distant metastasis. Conclusion: FDG-PET/CT is proven to be an effective method in detection of unsuspected-unknown metastasis, either in patients with solitary pulmonary lesion or in the initial staging of patients with NSCLC.

Anahtar Kelimeler:

18F-FDG, NSCLC, unsuspected and unknown metastases

The role of FDG-PET/CT in detecting unsuspected and unknown distant metastasis in the initial staging of NSCLC

Keywords:

18F-FDG, NSCLC, unsuspected and unknown metastases,

PDF

___

Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet 2000; 355: 479–485.
Janssen-Heijnen ML, Coebergh JW. Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe. Lung Cancer 2001; 31: 123–137. 3. Pantel K, Izbicki J, Passlick B, Angstwurm M, Häussinger K, Thetter O, Riethmüller G. Frequency and prognostic
significance of isolated tumour cells in bone marrow of patients
with non-small-cell lung cancer without overt metastases.
Dietlein M, Weber K, Gandjour A, Moka D, Theissen P, Lauterbach KW, Schicha H. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results. Eur J Nucl Med 2000; 27: 1598–1609.
Sogaard R, Fischer BM, Mortensen J, Hojgaard L, Lassen U. Preoperative staging of lung cancer with PET/CT: cost- effectiveness evaluation alongside a randomized controlled trial. Eur J Nucl Med Mol Imaging 2011; 38: 802–809.
Hellwig D, Ukena D, Paulsen F, Bamberg M, Kirsch CM. Meta- analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumors. Basis for discussion of the German Consensus Conference on PET in Oncology 2000. Pneumologie 2001; 55: 367–377.
Lardinois D, Weder W, Roudas M, von Schulthess GK, Tutic M, Moch H, Stahel RA, Steinert HC. Etiology of solitary extrapulmonary positron emission tomography and computed tomography findings in patients with lung cancer. J Clin Oncol 2005; 23: 6846–6853.
Verhagen AF, Bootsma GP, Tjan-Heijnen VC, van der Wilt GJ, Cox AL, Brouwer MH, Corstens FH, Oyen WJ. FDG-PET in staging lung cancer: how does it change the algorithm? Lung Cancer 2004; 44: 175–181.
Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001; 285: 914–924.
Quint LE, Tummala S, Brisson LJ, Francis IR, Krupnick AS, Kazerooni EA, Iannettoni MD, Whyte RI, Orringer MB. Distribution of distant metastases from newly diagnosed non- small cell lung cancer. Ann Thorac Surg 1996; 62: 246–250.
Prokop M, Galanski M. Spiral and Multislice Computed Tomography of the Body. Stuttgart, Germany: Thieme; 2003.
Schrevens L, Lorent N, Dooms C, Vansteenkiste J. The role of PET scan in diagnosis, staging, and management of non-small cell lung cancer. Oncologist 2004; 9: 633–643.
Little AG, Stitik FP. Clinical staging of patients with non-small cell lung cancer. Chest 1990; 97: 1431–1438.
Vesselle H, Pugsley JM, Vallieres E, Wood DE. The impact of fluorodeoxyglucose F 18 positron-emission tomography on the surgical staging of non-small cell lung cancer. J Thorac Cardiovasc Surg 2002; 124: 511–519.
Gupta NC, Graeber GM, Rogers JS 2nd, Bishop HA Comparative efficacy of positron emission tomography with FDG and computed tomographic scanning in preoperative staging of non-small cell lung cancer. Ann Surg 1999; 229: 286–291.
Scott WJ, Gobar LS, Terry JD, Dewan NA, Sunderland JJ. Mediastinal lymph node staging of non-small-cell lung cancer: a prospective comparison of computed tomography and positron emission tomography. J Thorac Cardiovasc Surg 1996; 111: 642–648.
Steinert HC, Hauser M, Allemann F, Engel H, Berthold T, von Schulthess GK, Weder W. Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology 1997; 202: 441–446.
Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Verschakelen JA, Nackaerts KL, Mortelmans LA. Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer: a prospective analysis of 50 cases. Leuven Lung Cancer Group. Chest 1997; 112: 1480–1486.
Bury T, Paulus P, Dowlati A, Corhay JL, Weber T, Ghaye B, Schoffers J, Limet R, Albert A, Rigo P et al. Staging of the mediastinum: value of positron emission tomography imaging in non-small cell lung cancer. Eur Respir J 1996; 9: 2560–2564.
Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, von Schulthess GK, Steinert HC. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003; 348: 2500– 2507.
De Wever W, Vankan Y, Stroobants S, Verschakelen J. Detection of extrapulmonary lesions with integrated PET/CT in the staging of lung cancer. Eur Respir J 2007; 29: 995–1002.
De Wever W, Ceyssens S, Mortelmans L, Stroobants S, Marchal G, Bogaert J, Verschakelen JA. Additional value of PET-CT in the staging of lung cancer: comparison with CT alone, PET alone and visual correlation of PET and CT. Eur Radiol 2007; 17: 23–32.
Cerfolio RJ, Ojha B, Bryant AS, Raghuveer V, Mountz JM, Bartolucci AA. The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer. Ann Thorac Surg 2004; 78: 1017– 1023.
Yi CA, Shin KM, Lee KS, Kim BT, Kim H, Kwon OJ, Choi JY, Chung MJ. Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging. Radiology 2008; 248: 632–642.
Quaia E, Tona G, Gelain F, Lubin E, Pizzolato R, Boscolo E, Bussoli L. Integrated fluorine-18 fluorodeoxyglucose (18F-FDG) PET/CT compared to standard contrast-enhanced CT for characterization and staging of pulmonary tumors eligible for surgical resection. Acta Radiol 2008; 49: 995–1004.
Tsushima Y, Tateishi U, Uno H, Takeuchi M, Terauchi T, Goya T, Kim EE. Diagnostic performance of PET/CT in differentiation of malignant and benign non-solid solitary pulmonary nodules. Ann Nucl Med 2008; 22: 571–577.
Hau NH, Ravel AC, Duclos A, Giammarile F, Souquet PJ. FDG-PET-CT and the diagnosis of malignancy of pulmonary nodules and mass lesions. Rev Mal Respir 2008; 25: 33–41.
Rankin SC. The role of positron emission tomography in staging of non-small cell lung cancer. Target Oncol 2008; 3: 149–159.
Krüger S, Buck AK, Mottaghy FM, Hasenkamp E, Pauls S, Schumann C, Wibmer T, Merk T, Hombach V, Reske SN. Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging 2009; 36: 1807–1812.
Posther KE, McCall LM, Harpole DH Jr, Reed CE, Putnam JB Jr, Rusch VW, Siegel BA. Yield of brain 18F-FDG PET in evaluating patients with potentially operable non-small cell lung cancer. J Nucl Med 2006; 47: 1607–1611.
Ludwig V, Komori T, Kolb D, Martin WH, Sandler MP, Delbeke D. Cerebral lesions incidentally detected on 2-deoxy-2-[18F] fluoro-D-glucose positron emission tomography images of patients evaluated for body malignancies. Mol Imaging Biol 2002; 4: 359–362.
Wiering B, Ruers TJ, Krabbe PF, Dekker HM, Oyen WJ. Comparison of multiphase CT, FDG-PET and intra-operative ultrasound in patients with colorectal liver metastases selected for surgery. Ann Surg Oncol 2007; 14: 818–826.
Metser U, Miller E, Lerman H, Lievshitz G, Avital S, Even- Sapir E. 18F-FDG PET/CT in the evaluation of adrenal masses. J Nucl Med 2006; 47: 32–37.
Brady MJ, Thomas J, Wong TZ, Franklin KM, Ho LM, Paulson EK. Adrenal nodules at FDG PET/CT in patients known to have or suspected of having lung cancer: a proposal for an efficient diagnostic algorithm. Radiology 2009; 250: 523–530.
Kumar R, Xiu Y, Yu JQ, Takalkar A, El-Haddad G, Potenta S, Kung J, Zhuang H, Alavi A. 18F-FDG PET in evaluation of adrenal lesions in patients with lung cancer. J Nucl Med 2004; 45: 2058–2062.
Marom EM, McAdams HP, Erasmus JJ, Goodman PC, Culhane DK, Coleman RE, Herndon JE, Patz EF Jr. Staging non-small cell lung cancer with whole-body PET. Radiology 1999; 212: 803–809.
Nakamoto Y, Osman M, Wahl RL. Prevalence and patterns of bone metastases detected with positron emission tomography using F-18 FDG. Clin Nucl Med 2003; 28: 302–307.
Bury T, Barreto A, Daenen F, Barthelemy N, Ghaye B, Rigo P. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 1998; 25: 1244–1247.
Cheran SK, Herndon JE 2nd, Patz EF Jr. Comparison of whole- body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. Lung Cancer 2004; 44: 317–325.
Song JW, Oh YM, Shim TS, Kim WS, Ryu JS, Choi CM. Efficacy comparison between (18)F-FDG PET/CT and bone scintigraphy in detecting bony metastases of non-small-cell lung cancer. Lung Cancer 2009; 65: 333–338.
MacManus MP, Hicks RJ, Matthews JP, Hogg A, McKenzie AF, Wirth A, Ware RE, Ball DL. High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys 2001; 50: 287–293.
Eschmann SM, Friedel G, Paulsen F, Reimold M, Hehr T, Scheiderbauer J, Budach W, Kotzerke J, Bares R. Impact of staging with 18F-FDG-PET on outcome of patients with stage III non-small cell lung cancer: PET identifies potential survivors. Eur J Nucl Med Mol Imaging 2007; 34: 54–59.
Reed CE, Harpole DH, Posther KE, Woolson SL, Downey RJ, Meyers BF, Heelan RT, MacApinlac HA, Jung SH, Silvestri GA et al. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg 2003; 126: 1943–1951.
[No authors listed.] Pretreatment evaluation of non-small-cell lung cancer. The American Thoracic Society and The European Respiratory Society. Am J Respir Crit Care Med 1997; 156: 320–332.
Opoka L, Kunikowska J, Podgajny Z, Błasińska-Przerwa K, Burakowska B, Oniszh K, Gola M, Langfort R, Rudziński P, Bestry I et al. Staging of non-small cell lung cancer using CT and integrated PET-CT. Pneumonol Alergol Pol 2013; 81: 5–15.